Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
<i>Introduction</i>: The co-presence of bronchiectasis (BE) in severe eosinophilic asthma (SEA) is common. Data about the effectiveness of benralizumab in patients with SEA and BE (SEA + BE) are lacking. <i>Aim</i>: The aim of this study was to evaluate the effectiveness of b...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/12/3953 |
| _version_ | 1797594152786984960 |
|---|---|
| author | Raffaele Campisi Santi Nolasco Corrado Pelaia Pietro Impellizzeri Maria D’Amato Andrea Portacci Luisa Ricciardi Giulia Scioscia Nunzio Crimi Nicola Scichilone Maria Pia Foschino Barbaro Girolamo Pelaia Giovanna Elisiana Carpagnano Alessandro Vatrella Claudia Crimi |
| author_facet | Raffaele Campisi Santi Nolasco Corrado Pelaia Pietro Impellizzeri Maria D’Amato Andrea Portacci Luisa Ricciardi Giulia Scioscia Nunzio Crimi Nicola Scichilone Maria Pia Foschino Barbaro Girolamo Pelaia Giovanna Elisiana Carpagnano Alessandro Vatrella Claudia Crimi |
| author_sort | Raffaele Campisi |
| collection | DOAJ |
| description | <i>Introduction</i>: The co-presence of bronchiectasis (BE) in severe eosinophilic asthma (SEA) is common. Data about the effectiveness of benralizumab in patients with SEA and BE (SEA + BE) are lacking. <i>Aim</i>: The aim of this study was to evaluate the effectiveness of benralizumab and remission rates in patients with SEA compared to SEA + BE, also according to BE severity. <i>Methods</i>: We conducted a multicentre observational study, including patients with SEA who underwent chest high-resolution computed tomography at baseline. The Bronchiectasis Severity Index (BSI) was used to assess BE severity. Clinical and functional characteristics were collected at baseline and after 6 and 12 months of treatment. <i>Results</i>: We included 74 patients with SEA treated with benralizumab, of which 35 (47.2%) showed the co-presence of bronchiectasis (SEA + BE) with a median BSI of 9 (7–11). Overall, benralizumab significantly improved the annual exacerbation rate (<i>p</i> < 0.0001), oral corticosteroids (OCS) consumption (<i>p</i> < 0.0001) and lung function (<i>p</i> < 0.01). After 12 months, significant differences were found between SEA and SEA + BE cohorts in the number of exacerbation-free patients [64.1% vs. 20%, OR 0.14 (95% CI 0.05–0.40), <i>p</i> < 0.0001], the proportion of OCS withdrawal [−92.6% vs. −48.6, <i>p</i> = 0.0003], and the daily dose of OCS [−5 mg (0 to −12.5) vs. −12.5 mg (−7.5 to −20), <i>p</i> = 0.0112]. Remission (zero exacerbations + zero OCS) was achieved more frequently in the SEA cohort [66.7% vs. 14.3%, OR 0.08 (95% CI 0.03–0.27), <i>p</i> < 0.0001]. Changes in FEV<sub>1</sub>% and FEF<sub>25–75%</sub> were inversely correlated with BSI (<i>r</i> = −0.36, <i>p</i> = 0.0448 and <i>r</i> = −0.41, <i>p</i> = 0.0191, respectively). <i>Conclusions</i>: These data suggest that benralizumab exerts beneficial effects in SEA with or without BE, although the former achieved less OCS sparing and fewer respiratory-function improvements. |
| first_indexed | 2024-03-11T02:19:33Z |
| format | Article |
| id | doaj.art-947d4d9ba77644afb1c195bfb1c01e61 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T02:19:33Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-947d4d9ba77644afb1c195bfb1c01e612023-11-18T10:58:58ZengMDPI AGJournal of Clinical Medicine2077-03832023-06-011212395310.3390/jcm12123953Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational StudyRaffaele Campisi0Santi Nolasco1Corrado Pelaia2Pietro Impellizzeri3Maria D’Amato4Andrea Portacci5Luisa Ricciardi6Giulia Scioscia7Nunzio Crimi8Nicola Scichilone9Maria Pia Foschino Barbaro10Girolamo Pelaia11Giovanna Elisiana Carpagnano12Alessandro Vatrella13Claudia Crimi14Respiratory Medicine Unit, Policlinico “G. Rodolico-San Marco” University Hospital, 95123 Catania, ItalyRespiratory Medicine Unit, Policlinico “G. Rodolico-San Marco” University Hospital, 95123 Catania, ItalyDepartment of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyDepartment of Respiratory Medicine, University “Federico II” of Naples, 80138 Naples, ItalyDepartment of Translational Biomedicine and Neuroscience, Institute of Respiratory Disease, University “Aldo Moro”, 70121 Bari, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98166 Messina, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, 71100 Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyDivision of Respiratory Diseases, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90128 Palermo, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, 71100 Foggia, ItalyDepartment of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Translational Biomedicine and Neuroscience, Institute of Respiratory Disease, University “Aldo Moro”, 70121 Bari, ItalyDepartment of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, ItalyRespiratory Medicine Unit, Policlinico “G. Rodolico-San Marco” University Hospital, 95123 Catania, Italy<i>Introduction</i>: The co-presence of bronchiectasis (BE) in severe eosinophilic asthma (SEA) is common. Data about the effectiveness of benralizumab in patients with SEA and BE (SEA + BE) are lacking. <i>Aim</i>: The aim of this study was to evaluate the effectiveness of benralizumab and remission rates in patients with SEA compared to SEA + BE, also according to BE severity. <i>Methods</i>: We conducted a multicentre observational study, including patients with SEA who underwent chest high-resolution computed tomography at baseline. The Bronchiectasis Severity Index (BSI) was used to assess BE severity. Clinical and functional characteristics were collected at baseline and after 6 and 12 months of treatment. <i>Results</i>: We included 74 patients with SEA treated with benralizumab, of which 35 (47.2%) showed the co-presence of bronchiectasis (SEA + BE) with a median BSI of 9 (7–11). Overall, benralizumab significantly improved the annual exacerbation rate (<i>p</i> < 0.0001), oral corticosteroids (OCS) consumption (<i>p</i> < 0.0001) and lung function (<i>p</i> < 0.01). After 12 months, significant differences were found between SEA and SEA + BE cohorts in the number of exacerbation-free patients [64.1% vs. 20%, OR 0.14 (95% CI 0.05–0.40), <i>p</i> < 0.0001], the proportion of OCS withdrawal [−92.6% vs. −48.6, <i>p</i> = 0.0003], and the daily dose of OCS [−5 mg (0 to −12.5) vs. −12.5 mg (−7.5 to −20), <i>p</i> = 0.0112]. Remission (zero exacerbations + zero OCS) was achieved more frequently in the SEA cohort [66.7% vs. 14.3%, OR 0.08 (95% CI 0.03–0.27), <i>p</i> < 0.0001]. Changes in FEV<sub>1</sub>% and FEF<sub>25–75%</sub> were inversely correlated with BSI (<i>r</i> = −0.36, <i>p</i> = 0.0448 and <i>r</i> = −0.41, <i>p</i> = 0.0191, respectively). <i>Conclusions</i>: These data suggest that benralizumab exerts beneficial effects in SEA with or without BE, although the former achieved less OCS sparing and fewer respiratory-function improvements.https://www.mdpi.com/2077-0383/12/12/3953benralizumabbiologicssevere asthmabronchiectasis |
| spellingShingle | Raffaele Campisi Santi Nolasco Corrado Pelaia Pietro Impellizzeri Maria D’Amato Andrea Portacci Luisa Ricciardi Giulia Scioscia Nunzio Crimi Nicola Scichilone Maria Pia Foschino Barbaro Girolamo Pelaia Giovanna Elisiana Carpagnano Alessandro Vatrella Claudia Crimi Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study Journal of Clinical Medicine benralizumab biologics severe asthma bronchiectasis |
| title | Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study |
| title_full | Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study |
| title_fullStr | Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study |
| title_full_unstemmed | Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study |
| title_short | Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study |
| title_sort | benralizumab effectiveness in severe eosinophilic asthma with co presence of bronchiectasis a real world multicentre observational study |
| topic | benralizumab biologics severe asthma bronchiectasis |
| url | https://www.mdpi.com/2077-0383/12/12/3953 |
| work_keys_str_mv | AT raffaelecampisi benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT santinolasco benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT corradopelaia benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT pietroimpellizzeri benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT mariadamato benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT andreaportacci benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT luisaricciardi benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT giuliascioscia benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT nunziocrimi benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT nicolascichilone benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT mariapiafoschinobarbaro benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT girolamopelaia benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT giovannaelisianacarpagnano benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT alessandrovatrella benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy AT claudiacrimi benralizumabeffectivenessinsevereeosinophilicasthmawithcopresenceofbronchiectasisarealworldmulticentreobservationalstudy |